2021
Optimal timing of post-operative enoxaparin after neurosurgery: A single institution experience
Briggs RG, Lin YH, Dadario NB, Young IM, Conner AK, Xu W, Tanglay O, Kim SJ, Fonseka RD, Bonney PA, Chakraborty AR, Nix CE, Flecher LR, Yeung JT, Teo C, Sughrue ME. Optimal timing of post-operative enoxaparin after neurosurgery: A single institution experience. Clinical Neurology And Neurosurgery 2021, 207: 106792. PMID: 34233235, DOI: 10.1016/j.clineuro.2021.106792.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisLower extremity deep vein thrombosisExtremity deep vein thrombosisIntracranial tumor resectionVenous thromboembolismAnticoagulant prophylaxisProphylactic enoxaparinTumor resectionImmediate post-operative periodMultivariate binomial logistic regression analysisNon-anticoagulation groupSingle institution experiencePost-operative periodPossible risk factorsPost-operative brain tumor patientsEvidence-based protocolsBrain tumor patientsLogistic regression analysisHigh-grade gliomasBinomial logistic regression analysisVTE complicationsElective craniotomyMedical comorbiditiesPulmonary embolismAdult patients
2020
Does neurofibromatosis 1 status impact outcomes for pediatric/young adults undergoing spinal fusion?
Freedman I, Koo A, Yeagle E, Diluna M, Kolb L, Yeung J. Does neurofibromatosis 1 status impact outcomes for pediatric/young adults undergoing spinal fusion? Surgical Neurology International 2020, 11: 60. PMID: 32363055, PMCID: PMC7193189, DOI: 10.25259/sni_39_2020.Peer-Reviewed Original ResearchNeurofibromatosis type 1Adverse postoperative eventsYoung adult patientsAdult patientsPostoperative eventsIndependent predictorsSpine patientsNF1 statusSpinal fusionNonroutine discharge dispositionNonroutine hospital dischargeFurther prospective studiesNationwide Inpatient SampleLength of staySignificant independent predictorsSpinal fusion surgeryYears of agePaucity of dataNonroutine dischargeMore transfusionsDischarge dispositionFusion patientsHospital dischargePerioperative variablesComplication rate
2013
LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma
Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H. LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. Clinical Cancer Research 2013, 19: 1816-1826. PMID: 23401227, PMCID: PMC3618546, DOI: 10.1158/1078-0432.ccr-12-2861.Peer-Reviewed Original ResearchConceptsHLA class IT cell infiltrationHLA class IILoss of heterozygosityHLA class IIIClass IOverall survivalAdult glioblastomaClass IIIHLA class I expressionHuman leukocyte antigen (HLA) class IClass IIEfficacy of immunotherapyShorter overall survivalCytotoxic T cellsClass I expressionAntigen class ICross-sectional analysisAdult patientsShorter survivalImmunohistochemical evaluationT cellsHLA class I regionI expressionDownregulated expression